La tuberculosis resistente al tratamiento
DOI:
https://doi.org/10.29105/cienciauanl27.123-6Palabras clave:
tuberculosis (TB), Mycobacterium tuberculosis, TB pulmonar, tratamiento, fármacos, resistenciaResumen
La tuberculosis (TB) es una enfermedad infecciosa originada principalmente por una bacteria denominada Mycobacterium tuberculosis, aunque existen otras especies del mismo género que también pueden ocasionarla (Brosch et al., 2002) (figura 1). A lo largo de la historia ha generado incontables muertes en todo el mundo, incluso se ha encontrado evidencia arqueológica de ésta en momias egipcias que datan del año 2,300 A.C. (Cave y Demonstrator, 1939). En la actualidad, la Organización Mundial de la Salud (OMS) reporta que en 2021 fue causa de muerte en 1.6 millones de personas (WHO, 2022a).
Descargas
Citas
Almeida Da Silva, P.E., y Palomino, J.C. (2011). Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother, 66:1417-30. DOI: https://doi.org/10.1093/jac/dkr173
Brosch, R., Gordon, S.V., Marmiesse, M., et al. (2002). A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proceedings of the National Academy of Sciences. 99: 3684-3689. DOI: https://doi.org/10.1073/pnas.052548299
Caminero, J. (2003). Guía de la tuberculosis para médicos especialistas. Ed. Unión Internacional Contra la Tuberculosis y Enfermedades Respiratorias (UICTER): París. Francia.
Cave, A., y Demonstrator, A. (1939). The evidence for the incidence of tuberculosis in ancient Egypt. British Journal of Tuberculosis. 33:142-152. DOI: https://doi.org/10.1016/S0366-0850(39)80016-3
Davies, P.D. (2003). The role of DOTS in tuberculosis treatment and control. American Journal of Respiratory Medicine. 2:203-209. DOI: https://doi.org/10.1007/BF03256649
Dooley, K.E., Hanna, D., Mave, V., et al. (2019). Advancing the development of new tuberculosis treatment regimens: the essential role of translational and clinical pharmacology and microbiology. PLoS Medicine. 16:e1002842. DOI: https://doi.org/10.1371/journal.pmed.1002842
Falzon, D., Schünemann, H.J., Harausz, E., et al. (2017). World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. European Respiratory Journal. 49. DOI: https://doi.org/10.1183/13993003.02308-2016
Fatima, S., Kumari, A., Das, G., et al. (2020). Tuberculosis vaccine: A journey from BCG to present. Life Sciences. 252:117594. DOI: https://doi.org/10.1016/j.lfs.2020.117594
Golden, M.P., y Vikram, H.R. (2005). Extrapulmonary tuberculosis: an overview. American Family Physician. 72:1761-1768.
Gygli, S.M., Borrell, S., Trauner, A., et al. (2017). Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives. FEMS Microbiology Reviews. 41:354-373. DOI: https://doi.org/10.1093/femsre/fux011
Jankute, M., Cox, J.A., Harrison, J., et al. (2015). Assembly of the mycobacterial cell wall. Annual Review of Microbiology. 69:405-423. DOI: https://doi.org/10.1146/annurev-micro-091014-104121
Palomino, J.C., y Martin, A. (2014). Drug resistance mechanisms in Mycobacterium tuberculosis. Antibiotics. 3:317-340. DOI: https://doi.org/10.3390/antibiotics3030317
Singh, R., Dwivedi, S.P., Gaharwar, U.S., et al. (2020). Recent updates on drug resistance in Mycobacterium tuberculosis. Journal of Applied Microbiology. 128:1547-1567. DOI: https://doi.org/10.1111/jam.14478
Udwadia, Z.F., Amale, R.A., Ajbani, K.K., et al. (2012). Totally drug-resistant tuberculosis in India. Clinical Infectious Diseases. 54:579-581. DOI: https://doi.org/10.1093/cid/cir889
World Health Organization. (2006). The global plan to stop TB, 2006-2015. World Health Organization.
World Health Organization. (2022a). Global Tuberculosis Report 2022. World Health Organization. 68.
World Health Organization. (2022b). WHO consolidated guidelines on tuberculosis. Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update. World Health Organization.
